Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2017

Open Access 01-12-2017 | Retraction Note

Retraction Note to: Mutation pattern is an influential factor on functional mutation rates in cancer

Authors: Chuance Du, Xiaoyuan Wu, Jia Li

Published in: Cancer Cell International | Issue 1/2017

Login to get access

Excerpt

The authors are retracting this article [1] because they do not have ownership of the data they report. A formal investigation by the Institut de Biologie Intégrative de la Cellule (I2BC), Gif-Sur-Yvette, France, has found that the methods and analyses presented in Figures 1, 3 and 5 and all computer analyses were performed at the Institut de Biologie Intégrative de la Cellule (I2BC) and the data have been previously reported in [2]. All authors agree with this retraction. …
Literature
1.
2.
Li J, Poursat M-A, Drubay D, Motz A, Saci Z, Morillon A, Michiels S, Gautheret D. A dual model for prioritizing cancer mutations in the non-coding genome based on germline and somatic events. PLoS Comput Biol. 2015;11(11):e1004583.CrossRefPubMedPubMedCentral
Metadata
Title
Retraction Note to: Mutation pattern is an influential factor on functional mutation rates in cancer
Authors
Chuance Du
Xiaoyuan Wu
Jia Li
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2017
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-017-0436-4

Other articles of this Issue 1/2017

Cancer Cell International 1/2017 Go to the issue

Primary Research

HNRNPA2B1 regulates the epithelial–mesenchymal transition in pancreatic cancer cells through the ERK/snail signalling pathway

Primary Research

Anticancer properties of ester derivatives of betulin in human metastatic melanoma cells (Me-45)

Primary research

MiR–20a-5p promotes radio-resistance by targeting Rab27B in nasopharyngeal cancer cells

Primary research

Global expression profile of tumor stem-like cells isolated from MMQ rat prolactinoma cell

Primary research

Effect of RAGE gene polymorphisms and circulating sRAGE levels on susceptibility to gastric cancer: a case–control study

Primary Research

MYCN amplification predicts poor prognosis based on interphase fluorescence in situ hybridization analysis of bone marrow cells in bone marrow metastases of neuroblastoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits